Okapi Medical this week appointed Darren Obrigkeit as CEO and announced the successful pre-clinical study of the company’s wound closure technology.
Obrigkeit has more than 20 years of experience in the medical device industry and has held leadership roles internationally for startups and large companies.
“I’m thrilled to join the Okapi team,” Obrigkeit said in a news release. “This company is positioned to have a massive impact in the healthcare market with product that can change the medical adhesive space dynamically.”
The hiring comes after the company said it had a successful pre-clinical study involving its Cutiva wound closure technology. The technology uses a fine-tuned cyanoacrylate chemistry for specific healthcare applications.
“This represents the next generation in wound closure,” cofounder David Kay said. “Cutiva excels where existing adhesives fall short and breathes new life into options for closing wounds. This unique chemistry enables the creation of truly dynamic, skin-like adhesives for the first time. Cutiva will allow for far superior wound healing in an entirely cost-effective way.”
Okapi said it is continuing to develop its unique closure system on the heels of the successful pre-clinical study.
“We are zeroing in on the adhesive while developing an entire closure system. Our next stage of development will include applicators, instruments and other products aimed to speed and simplify the procedure,” Obrigkeit said.